Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TxCell, a France-based biotechnology company, has presented the final positive results of the phase I/II study in Crohn's disease (CATS-1) which assessed the product candidate, OvaSave.
Subscribe to our email newsletter
The open label, multicenter phase I/II study comprising 20 patients evaluated the tolerability and efficacy of OvaSave, an antigen-specific regulatory T cell-based immunotherapy.
The data demonstrated that OvaSave was well tolerated, where 40% of the patients positively responded five weeks after treatment in the overall population group.
The positive data of this study has led the company to take up the initiation of phase II study in the same patient population.